DB05427ExperimentalVaccines
IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. It includes... It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells.
- Mechanism
- Curator reviewed
IDD-3 is well tolerated with evidence of efficacy and induction of immune response in patients with progressive metastatic melanoma.
- Primary indication
- Investigated for use/treatment in melanoma.Curator reviewed
What you can answer from here — as of April 02, 2025
Which companies are running trials of IDD-3, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account